Morgan Stanley Maintains Equal-Weight on Alnylam Pharmaceuticals, Raises Price Target to $183
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley analyst Michael Ulz has maintained an Equal-Weight rating on Alnylam Pharmaceuticals and raised the price target from $175 to $183.
November 03, 2023 | 12:22 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Morgan Stanley has maintained an Equal-Weight rating on Alnylam Pharmaceuticals and raised the price target from $175 to $183.
The news is directly about Alnylam Pharmaceuticals. The raised price target by Morgan Stanley indicates a positive outlook for the company, which could lead to an increase in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100